Blow For Prestige As Trastuzumab Biosimilar Rejected By EMA

Tuznue And Hervelous Rivals To Herceptin Receive Negative Opinions From CHMP

EU flag thumbs down
The CHMP has refused to endorse Prestige Biopharma’s trastuzumab • Source: Shutterstock

More from Biosimilars

More from Products